September 18, 2019

Dr. Robert Petit Follows His Passion to OS Therapies as Chief Medical & Scientific Advisor

WASHINGTON--(BUSINESS WIRE)-- **OS Therapies,** a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS), today announced the appointment of Robert Petit, Ph.D., as its Chief Medical and Scientific Advisor. He is continuing to support the technology that he helped to develop at Advaxis.

Dr. Petit is a highly successful C-level executive and biopharma leader with a diverse background in research and development with over 25 years of experience in clinical development, and pre-clinical and translational research. In addition, he has helped to build, grow and secure investments for respected academic organizations, as well as private and publicly traded biopharma companies. An accomplished immuno-oncology scientist, innovator and drug developer, he has been integral to 7 NDA/BLA/EMA filings in the immuno-oncology space and was part of team at BMS who established the first checkpoint inhibitor therapy. Most recently, Dr. Petit served as Chief Scientific Officer of Advaxis, Inc., contributing to their successful NASDAQ IPO, raising significant capital, and evolving their platform technology to leverage both personal and shared neoantigens.

"I am excited to join the OS Therapies team and contribute toward realizing the potential of the OS Therapies lead program in the treatment of osteosarcoma," said Dr. Petit. "I also look forward to furthering the mission of OS Therapies by assisting in building a pipeline of assets that will improve treatment options and outcomes for patients with osteosarcoma."

"From our first meeting with Advaxis to discuss out-licensing for the Osteosarcoma indication, we knew Robert was the driving force behind the development of the technology," said Paul Romness, Chief Executive Officer of OS Therapies. "Already, he has been a crucial contributor to our team in bringing knowledge and passion for the technology. As our Chief Medical and Scientific Advisor, he is set to bring even more confidence and institutional knowledge to our investors and clinical researchers alike."

About OS Therapies

OS Therapies Inc. (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS). OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years.

For more information, please see the Company's website at www.ostherapies.com

View source version on businesswire.com:
https://www.businesswire.com/news/home/20190918005918/en/

Media Contact:
Paul Romness, CEO, OS Therapies
media@ostherapies.com

Source: OS Therapies Inc.